TY - JOUR
T1 - MicroRNA: Siglec crosstalk in cancer progression
AU - Mustafov, Denis
AU - Ahmad, Mohammed Saqif
AU - Serrano, Antonio
AU - Braoudaki, Maria
AU - Siddiqui, Shoib
N1 - © 2024 Author(s). . Published by Elsevier Ltd. This is an open access article distributed under the Creative Commons Attribution License, to view a copy of the license, see: https://creativecommons.org/licenses/by/4.0/
PY - 2024/8/30
Y1 - 2024/8/30
N2 - Aberrant Siglec expression in the tumour microenvironment has been implicated in tumour malignancies and can impact tumour behaviour and patient survival. Further to this, engagement with sialoglycans induces masked antigen recognition and promotes immune evasion, highlighting deregulated immune function. This necessitates the elucidation of their expression profiles in tumour progression. MicroRNAs (miRNAs) mediated targeting represents a novel approach to further elucidate Siglec potential and clinical relevance. Although miRNA activity in Siglec expression remains limited, we highlight current literature detailing miRNA:Siglec interactions within the tumour landscape and provide insights for possible diagnostic and therapeutic strategies in targeting the Siglec/sialic acid axis.
AB - Aberrant Siglec expression in the tumour microenvironment has been implicated in tumour malignancies and can impact tumour behaviour and patient survival. Further to this, engagement with sialoglycans induces masked antigen recognition and promotes immune evasion, highlighting deregulated immune function. This necessitates the elucidation of their expression profiles in tumour progression. MicroRNAs (miRNAs) mediated targeting represents a novel approach to further elucidate Siglec potential and clinical relevance. Although miRNA activity in Siglec expression remains limited, we highlight current literature detailing miRNA:Siglec interactions within the tumour landscape and provide insights for possible diagnostic and therapeutic strategies in targeting the Siglec/sialic acid axis.
U2 - 10.1016/j.cbpa.2024.102502
DO - 10.1016/j.cbpa.2024.102502
M3 - Review article
SN - 1879-0402
VL - 81
SP - 1-!0
JO - Current Opinion in Chemical Biology
JF - Current Opinion in Chemical Biology
M1 - , August 2024, 102502
ER -